Detail akcie Eisai online

Business Summary: Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the three months ended 30 June 2025, Eisai Co Ltd revenues increased 7% to Y202.65B. Net income applicable to common stockholders increased 37% to Y14.47B. Revenues reflect Pharmaceutical Business segment increase of 6% to Y198.45B, Other Business segment increase of 70% to Y4.2B, China segment increase of 21% to Y36.46B, Japan segment increase of 6% to Y56.05B, Asia/Latin America segment increase of 13% to Y16.13B.